4DMT appoints CFO Kristian Humer as Principal Accounting Officer

4D Molecular Therapeutics, Inc.

Appointment effective March 25, 2026; Humer succeeds Ashoo Gupta.
Humer continues as CFO and Principal Financial Officer (role since Nov 2025).
Prior roles include CFO at Foghorn Therapeutics (Apr 2024–Nov 2025) and Viridian Therapeutics.
Gupta remains Vice President, Finance and Controller of the company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.